<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03223883</url>
  </required_header>
  <id_info>
    <org_study_id>201710769</org_study_id>
    <nct_id>NCT03223883</nct_id>
  </id_info>
  <brief_title>Curcumin and Vascular and Cognitive Function in Patients With Chronic Kidney Disease</brief_title>
  <official_title>Curcumin Supplementation for Improving Vascular and Cognitive Function in Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diana Jalal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Colorado, Boulder</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed research is clinical study evaluating the therapeutic benefits of curcumin on&#xD;
      vascular function in patients with chronic kidney disease (CKD). The study aims to establish&#xD;
      that curcumin will improve endothelial function and reduce large artery stiffness by reducing&#xD;
      oxidative stress and in conjunction with lowering markers of inflammation and oxidative&#xD;
      stress. In addition, the study will evaluate the potential benefit of curcumin on cognitive&#xD;
      function in patients with CKD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with chronic kidney disease (CKD) are at increased risk of death from cardiovascular&#xD;
      disease (CVD). Inflammation, oxidative stress and vascular dysfunction (impaired endothelial&#xD;
      function and increased large elastic artery stiffness), are highly prevalent in CKD and&#xD;
      contribute to the high incidence of CVD in this patient population. In addition, patients&#xD;
      with CKD suffer from high rates of cognitive decline for which we lack effective therapies.&#xD;
      Thus, therapeutic interventions targeting inflammation, oxidative stress, vascular&#xD;
      dysfunction, and cognitive impairment in CKD are a biomedical priority.&#xD;
&#xD;
      Curcumin is a natural polyphenol with anti-inflammatory and antioxidant characteristics. It&#xD;
      is safe and widely-available. Preliminary data in old mice and healthy middle-aged (MA)/older&#xD;
      adult humans indicate that curcumin administration improves endothelial dysfunction and large&#xD;
      artery stiffness by reducing oxidative stress and inflammation. Additionally, 12 weeks of&#xD;
      curcumin supplementation improves episodic memory in MA/older adults.&#xD;
&#xD;
      The primary goal of this R01 application is to extend previous findings in healthy MA/older&#xD;
      adults to patients with CKD, a growing clinical population with extensive baseline vascular&#xD;
      dysfunction and cognitive impairment who presently have few treatment options. The hypothesis&#xD;
      is that curcumin improves vascular endothelial function and large elastic artery stiffness in&#xD;
      MA/older adults with stage IIIb and IV CKD (estimated GFR 15-45 mL/min/1.73m2). The possible&#xD;
      mechanisms by which curcumin improves vascular function will be evaluated as well as whether&#xD;
      curcumin improves cognitive function in these patients.&#xD;
&#xD;
      Specific aim 1a will determine if 12 months of curcumin supplementation will improve brachial&#xD;
      artery-flow mediated dilation (BA-FMD) (endothelial function) and aortic pulse wave velocity&#xD;
      (aPWV) (arterial stiffness) compared to placebo (randomized placebo-controlled double-blind&#xD;
      study). Specific aim 1b will evaluate whether the curcumin-induced improvements in BA-FMD and&#xD;
      aPWV are mediated by reduced oxidative stress, and will evaluate the effects of curcumin on&#xD;
      systemic and endothelial cell markers of inflammation and oxidative stress. Importantly,&#xD;
      specific aim 2 will evaluate the effects of curcumin supplementation on cognitive function,&#xD;
      an important complication of CKD, using the NIH Cognitive Toolbox Battery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 30, 2018</start_date>
  <completion_date type="Anticipated">August 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized Double-Blind Placebo-Controlled Clinical Trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Patient, providers, and the investigative team will all be blinded to the randomization.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Vascular endothelial function</measure>
    <time_frame>12 months</time_frame>
    <description>Brachial artery flow-mediated dilation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Large artery stiffness</measure>
    <time_frame>12 months</time_frame>
    <description>Aortic pulse wave velocity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive function</measure>
    <time_frame>12 months</time_frame>
    <description>NIH toolbox battery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Chronic Kidney Diseases</condition>
  <condition>Cognitive Decline</condition>
  <arm_group>
    <arm_group_label>Curcumin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive curcumin (Lonvida) 2000 mg PO once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive placebo pill identical in appearance and taste to the supplement</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Curcumin</intervention_name>
    <description>Oral supplement for 12 months</description>
    <arm_group_label>Curcumin</arm_group_label>
    <other_name>Longvida</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral placebo for 12 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  CKD stage IIIB and IV&#xD;
&#xD;
          -  BMI&lt;35 kg/m2&#xD;
&#xD;
          -  Able to give informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Consuming a diet rich in curcumin or taking curcumin supplements in the past 12 months&#xD;
&#xD;
          -  Life expectancy &lt;1 year&#xD;
&#xD;
          -  Pregnant, breastfeeding, or unwilling to use adequate birth control&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Severe liver disease&#xD;
&#xD;
          -  Severe congestive heart failure&#xD;
&#xD;
          -  Hospitalization within the last 3 months&#xD;
&#xD;
          -  Active infection or antibiotic therapy&#xD;
&#xD;
          -  Immunosuppressive therapy within the last year&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diana Jalal</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diana Jalal</last_name>
    <phone>7204254154</phone>
    <email>diana-jalal@uiowa.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana I Jalal, MD</last_name>
      <phone>319-356-4113</phone>
      <email>diana-jalal@uiowa.edu</email>
    </contact>
    <contact_backup>
      <last_name>Debra O'Connell, BA</last_name>
      <phone>319-356-1693</phone>
      <email>debra-oconnell-moore@uiowa.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Diana I Jalal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>July 18, 2017</study_first_submitted>
  <study_first_submitted_qc>July 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2017</study_first_posted>
  <last_update_submitted>November 2, 2020</last_update_submitted>
  <last_update_submitted_qc>November 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Diana Jalal</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

